Hosted on MSN1mon
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...
Business Wire1mon
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...